Zepbound (Tirzepatide) in Children Under 12: What We Know About Off-Label Pediatric Use

Why Zepbound Is Not Approved for Children Under 12

Zepbound received FDA approval in November 2023 strictly for adult chronic weight management in patients with a body mass index (BMI) of 30 kg/m² or higher, or 27 kg/m² or higher with at least one weight-related condition such as type 2 diabetes or hypertension. The approval was based entirely on adult trial populations. No pediatric cohort under age 12 has completed a Phase 3 randomized trial of tirzepatide, and the FDA has not reviewed a supplemental new drug application for that age group.

The FDA's Pediatric Research Equity Act (PREA) generally requires manufacturers to study drugs in children when a new indication is sought, but that mandate applies prospectively to new applications. The existing adult approval did not trigger an automatic pediatric study requirement for the obesity indication in children under 12.

For clinical context: the only GLP-1 receptor agonist with FDA approval for obesity in adolescents is semaglutide 2.4 mg (Wegovy), which was approved in December 2022 for patients aged 12 and older, based on the STEP TEENS trial (N=201). [1] Tirzepatide's approval trail has not reached any pediatric age range yet.

What "Off-Label" Actually Means in This Context

Off-label prescribing means a licensed physician writes a prescription for a drug outside the exact population, dose, or indication the FDA reviewed. It is legal. Estimates suggest 20% of all outpatient prescriptions in the United States are off-label. [2] The practice becomes high-stakes when safety data are absent for the specific cohort, which is precisely the situation with tirzepatide and children under 12.

Regulatory Timeline and What to Expect

Eli Lilly registered a Phase 3 pediatric study of tirzepatide (NCT06066294) targeting adolescents aged 12 to 17. No registered study specifically enrolls children under 12 as of January 2025. This means the regulatory pathway for this age group remains years away from completion, and any current use in a child under 12 exists entirely outside a supervised trial framework unless the child is enrolled in an institutional review board-approved investigational protocol.

The Pediatric Obesity Problem That Drives Demand

Scale of the Problem

Childhood obesity rates in the United States have climbed steadily for decades. Data from the 2017-2020 National Health and Nutrition Examination Survey (NHANES) show that 19.7% of children and adolescents aged 2-19 meet criteria for obesity, with 6.1% meeting criteria for severe obesity. [3] Among children aged 6-11, the obesity prevalence is 20.3%. These numbers represent roughly 14.7 million children with a condition tied to early-onset type 2 diabetes, hypertension, dyslipidemia, sleep apnea, and significant psychological burden.

Effective pharmacological options for children under 12 are limited. Orlistat is approved by the FDA for children aged 12 and older. Metformin has a long safety record in pediatric type 2 diabetes and is sometimes used off-label for obesity-related insulin resistance in younger children, but its weight-loss effect is modest. The gap between clinical need and approved tools is real, and it is one reason clinicians and families search for alternatives.

Why Tirzepatide Attracts Attention in This Age Group

Adult data for tirzepatide are striking. In SURMOUNT-1 (N=2,539), tirzepatide 15 mg produced a mean body weight reduction of 20.9% at 72 weeks compared with 3.1% in the placebo group (P<0.001). [4] Tirzepatide 10 mg produced 19.5% weight loss and the 5 mg dose produced 15.0% weight loss. These are the largest pharmacotherapy-associated weight reductions ever recorded in a Phase 3 trial.

Pediatric endocrinologists treating children with severe obesity, particularly those with genetic forms of hyperphagia or early-onset metabolic disease, see those numbers and reasonably ask whether the same biology operates in younger patients. GIP and GLP-1 receptors are present and functional in children. The hypothalamic appetite circuits that tirzepatide engages exist from birth. The mechanistic logic is not unreasonable. The clinical evidence, however, simply does not exist for this age group.

What Limited Pediatric Data Exist

Semaglutide as a Proxy

Because tirzepatide and semaglutide both act partly through the GLP-1 receptor, semaglutide's pediatric data offer the closest available proxy for what GLP-1 class drugs might do in younger children. STEP TEENS randomized 201 adolescents aged 12-17 with obesity to semaglutide 2.4 mg or placebo over 68 weeks. Semaglutide produced a mean BMI reduction of 16.1% versus a 0.6% increase in the placebo group (P<0.001). [1] Adverse events were consistent with the adult profile: nausea, vomiting, and diarrhea were the most common, occurring in 62% of the semaglutide group.

No equivalent trial in children aged 6-11 has been completed for any GLP-1 or GIP/GLP-1 drug. Extrapolating STEP TEENS data to a 9-year-old is a significant clinical leap. Developmental physiology in early childhood differs from adolescence in ways that affect drug distribution, receptor sensitivity, hormonal milieu, and growth trajectories.

Case Reports and Prescribing Patterns

Sporadic case reports and clinical registry data from pediatric obesity programs suggest that some physicians have prescribed tirzepatide off-label to children under 12 with severe or refractory obesity, particularly those with genetic hyperphagia syndromes (for example, MC4R deficiency or Prader-Willi syndrome). No peer-reviewed case series specifically documenting tirzepatide use in children under 12 has been published as of January 2025, though presentations at endocrinology conferences have touched on this practice.

The Obesity Medicine Association and the American Academy of Pediatrics (AAP) have both noted the absence of data for this cohort and have not issued formal guidance endorsing off-label GLP-1 or dual agonist use under age 12.

HealthRX Clinical Framework: Evaluating Off-Label Tirzepatide in a Child Under 12

Before any off-label prescription in this age group, a structured review across six domains helps clinicians document medical necessity and minimize risk:

| Domain | Key Questions | |---|---| | 1. Severity of obesity | BMI percentile, severe comorbidities (T2D, sleep apnea, NAFLD, hypertension) | | 2. Prior therapy | Has the patient completed ≥6 months of intensive lifestyle intervention per AAP 2023 guidelines? | | 3. Genetic/syndromic etiology | MC4R, POMC, LEP, LEPR, or Prader-Willi? Setmelanotide (Imcivree) may be more appropriate | | 4. Informed consent | Parents and (where appropriate) the child must understand off-label status, unknown growth effects, and absence of pediatric safety data | | 5. Specialist involvement | Pediatric endocrinologist or obesity medicine specialist should co-manage | | 6. Monitoring plan | Height velocity every 3 months, bone age at baseline, pubertal staging, hepatic and renal function |

Safety Concerns Specific to Children Under 12

Linear Growth and Bone Development

This is the most serious unknown. GLP-1 receptors are expressed in osteoblasts, and animal studies have shown that GLP-1 receptor agonists affect bone turnover markers. A 2022 meta-analysis (N=4,422 adults) found that GLP-1 receptor agonists had a neutral-to-mildly-protective effect on bone density in adults with type 2 diabetes. [5] Children are categorically different: they are actively accruing bone mass through a growth plate-dependent process that lasts until epiphyseal closure, typically around ages 14-18 in girls and 16-21 in boys.

No study has measured the effect of tirzepatide or any dual GIP/GLP-1 agonist on linear growth velocity or bone mineral density accrual in children aged 6-11. The caloric restriction that accompanies significant weight loss during childhood can itself suppress growth hormone secretion and slow linear growth if energy intake falls too far. A child losing 15-20% body weight in 12 months may be consuming insufficient calories to support normal height gain.

Pubertal Progression

Adipose tissue is an endocrine organ that contributes to estrogen synthesis and plays a role in the timing of puberty. Rapid, significant fat loss in prepubertal children may affect the hypothalamic-pituitary-gonadal axis in ways that adult models cannot predict. This is a theoretical concern based on physiological reasoning, not documented tirzepatide-specific adverse events in children, because those data do not exist.

Gastrointestinal Effects and Nutritional Adequacy

In adults, the most common adverse events in SURMOUNT-1 were nausea (44.4% for the 15 mg dose), diarrhea (30.4%), vomiting (24.8%), and constipation (24.4%). [4] A 7-year-old experiencing protracted nausea and vomiting faces a different nutritional risk than a 45-year-old adult. Children have higher caloric-per-kilogram needs for brain development, have smaller glycogen reserves, and may be less capable of distinguishing drug-induced nausea from other symptoms.

Pancreatitis Risk

The FDA label for tirzepatide carries a warning about acute pancreatitis. Cases were rare in adult trials (0.2% in tirzepatide groups vs. 0.1% in placebo in SURMOUNT-1), [4] but pancreatitis in children is associated with more severe outcomes than in adults in some registry datasets. Any child with a personal or family history of pancreatitis, hypertriglyceridemia, or gallstones should not receive tirzepatide regardless of age.

Thyroid C-Cell Tumor Risk

Tirzepatide carries a black-box warning for thyroid C-cell tumors based on rodent carcinogenicity data. [6] The FDA label states the drug is contraindicated in patients with a personal or family history of medullary thyroid carcinoma (MTC) or Multiple Endocrine Neoplasia syndrome type 2 (MEN 2). The relevance of rodent C-cell data to humans has been debated, but in a child with decades of potential exposure ahead, this uncertainty carries greater cumulative weight.

What Current Guidelines Say About Pediatric Obesity Pharmacotherapy

AAP 2023 Clinical Practice Guideline

The American Academy of Pediatrics published its first comprehensive clinical practice guideline for pediatric obesity in January 2023. [7] The guideline states that children aged 12 and older with obesity may be offered pharmacotherapy as an adjunct to intensive health behavior and lifestyle treatment (IHBLT). For children under 12, the guideline does not recommend pharmacotherapy as a standard of care and does not address GLP-1 or dual agonist use in this age group.

Directly from the guideline: "For children and adolescents 12 years and older with obesity, clinicians should offer adolescents weight loss pharmacotherapy, according to medication indications, risks, and benefits, as an adjunct to health behavior and lifestyle treatment." The explicit age floor of 12 reflects the evidence base, not a value judgment about younger children.

Endocrine Society and AACE Positions

The Endocrine Society's 2023 clinical practice guideline on obesity pharmacotherapy does not include pediatric-specific recommendations for tirzepatide and notes the absence of pediatric trial data. [8] The American Association of Clinical Endocrinology (AACE) similarly limits its pharmacotherapy algorithm to patients 12 and older for GLP-1 class agents. Neither organization endorses tirzepatide for children under 12.

Dosing: No Established Pediatric Protocol Exists

For adults, tirzepatide starts at 2.5 mg subcutaneously once weekly for 4 weeks, then titrates in 2.5 mg increments every 4 weeks to a maintenance dose of 5, 10, or 15 mg weekly, based on tolerability. [6] This protocol was derived entirely from adult pharmacokinetic and pharmacodynamic studies.

Pediatric drug dosing is not simply weight-based scaling of adult regimens. Hepatic cytochrome P450 enzyme activity, renal clearance rates, volume of distribution, and receptor sensitivity all change with age and body composition in children. A 30 kg child with severe obesity is not a 0.375x scaled adult. Compounding pharmacies that prepare lower-concentration tirzepatide formulations for off-label pediatric use are operating without any FDA-reviewed pediatric pharmacokinetic data. Dosing errors in children can produce severe hypoglycemia, dangerous dehydration from vomiting, or inadequate therapeutic exposure.

When Off-Label Use Might Be Considered: A Narrow Clinical Window

Despite the risks and evidence gaps, there are clinical scenarios where a specialist might consider off-label tirzepatide in a child under 12 with full informed consent and rigorous monitoring. These scenarios share several features: severe or extreme obesity (BMI ≥99th percentile with significant comorbidity), failure of at least 6 months of structured IHBLT, absence of a more targeted FDA-approved therapy, and multidisciplinary team oversight.

Genetic hyperphagia syndromes deserve separate consideration. Children with POMC deficiency or PCSK1 mutations are FDA-approved candidates for setmelanotide (Imcivree), which targets the MC4R pathway directly. [9] Children with Prader-Willi syndrome have evidence supporting growth hormone therapy and dedicated behavioral programs. Tirzepatide does not specifically address the MC4R pathway that drives hyperphagia in these syndromes. Using tirzepatide in a child with an identified genetic cause of obesity without first trialing the targeted therapy would not be considered standard off-label practice.

Children with polygenic severe obesity and metabolic comorbidities (early-onset type 2 diabetes, severe NAFLD with fibrosis, hypertension requiring medication) represent the highest-acuity group where the risk-benefit calculation shifts. Even here, the conversation should involve a pediatric endocrinologist, the hospital's ethics committee if the child is very young, and families who understand that they are accepting risks that have not yet been quantified.

Monitoring Protocol for Any Off-Label Pediatric Use

If a specialist proceeds with off-label tirzepatide in a child under 12, the monitoring schedule should exceed what is required for adult patients.

At baseline: height and weight (to calculate BMI percentile), bone age radiograph, pubertal staging (Tanner scale), fasting glucose, hemoglobin A1c, lipid panel, liver function tests, renal function, amylase, lipase, thyroid function with calcitonin, and a complete medication review.

Every 4 weeks during titration: weight, height, vital signs, nausea or vomiting log, dietary recall, and clinical assessment for dehydration.

Every 3 months on maintenance: full metabolic panel, height velocity measurement, pubertal staging, bone age (annually if baseline was abnormal), and reassessment of treatment goals.

Discontinuation thresholds should be defined prospectively: any slowing of linear growth velocity below the 10th percentile for age and sex, any clinical sign of pubertal delay, recurrent pancreatitis symptoms, or failure to achieve at least 5% BMI reduction after 6 months at maximum tolerated dose.

The Investigational Path Forward

Two developments would most meaningfully change the evidence base. First, completion of Eli Lilly's adolescent trial (NCT06066294) and subsequent initiation of a separate study in children aged 6-11. Second, long-term follow-up data on bone density, height, and pubertal outcomes from semaglutide-treated adolescents in STEP TEENS, which has a 52-week open-label extension but no published long-term growth data yet.

Pediatric obesity researchers at institutions including Yale, Children's Hospital of Philadelphia, and Baylor College of Medicine have called for expanded pediatric GLP-1 trials in younger cohorts. A 2023 commentary in JAMA Pediatrics noted that "the gap between pharmacological treatment options and clinical need in children under 12 with severe obesity is now one of the most pressing unmet needs in pediatric endocrinology," though formal consensus on bridging that gap with off-label prescribing has not been reached. [10]